Luc Mainville

All filings by Luc Mainville on record concern Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). In total, 12 filings cover trades dated from 21 July 2016 to 27 December 2017.

The open-market record is one-sided, with 11 purchases worth €160k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2017 to date brings 8 purchases and no sales.

Half of the purchases are above €8,867 and half below. Across 11 purchases, this insider has always bought alone, with no colleague buying within 30 days.

Most recently, on 27 December 2017, the filings show an open-market purchase worth €5,542 in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). The median gap between a trade and its publication by SEDI is 3 days. That lag is the time during which only the insider knows about the trade. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.